



Japan Society of Pharmaceutical Machinery  
and Engineering (JSPME)

8054 '03 NOV -6 11:03

October 31, 2003

Dockets Management Branch (HFA-305)  
Food and Drug Administration (FDA)  
5630 Fishers Lane, rm. 1061  
Rockville, MD 20852  
U.S.A.

Re: Docket No. 03D-0382, CDER 1997112

Dear Sir/Madam:

We, Japan Society of Pharmaceutical Machinery and Engineering (JSPME) are pleased to submit you our offers and comments concerning "Draft Guidance for Industry on Sterile Drug Products Produced by Aseptic Processing" (Docket No. 03D-0382, CDER 1997112). We hope that you will consider our comments, and this guidance will be a very fruitful guidance for PAT. This document prepared by using Microsoft® Word 2002 is also sent to [FDA\(coryj@cder.fda.gov\)](mailto:FDA(coryj@cder.fda.gov)) by e-mail today.

We would be much obliged if you give us FDA review of our comments by letter or by e-mail.

Contacts;

Katsuhide Terada, Ph. D.

Chairman of the Japan Society of Pharmaceutical Machinery and Engineering (JSPME)

Merino Bldg. 5<sup>th</sup> floor, 1-28 Kanda Suda-cho,  
Chiyoda-ku, Tokyo 101-0041

Japan

Tel: +81-3-3252-3048

E-mail: [info@seikiken.or.jp](mailto:info@seikiken.or.jp)

2003D-0382

070

For your references, we, Japan Society of Pharmaceutical Machinery and Engineering (JSPME) are nonprofit industry group which is operated mainly in Japan with approx. 810 members, and we were established Oct. 1990 in order to seek the ideal pharmaceutical production through the research, development and discussion based on both theoretical and practical concept in cooperating with industry, government and academia.

Sincerely,



Katsuhide Terada, Ph. D.

Chairman

Japan Society of Pharmaceutical Machinery and Engineering (JSPME)

Merino Bldg. 5<sup>th</sup> floor, 1-28 Kanda Suda-cho,

Chiyoda-ku, Tokyo 101-0041

Japan

Tel: +81-3-3252-3048

E-mail: [info@seikiken.or.jp](mailto:info@seikiken.or.jp)



C  
Japan Society of Pharmaceutical Machinery  
and Engineering (JSPME)

8054 03 NOV -6 11:03

October 31, 2003

Dockets Management Branch (HFA-305)  
Food and Drug Administration (FDA)  
5630 Fishers Lane, rm. 1061  
Rockville, MD 20852  
U.S.A.

Re: Docket No. 03D-0382, CDER 1997112

Dear Sir/Madam:

We, Japan Society of Pharmaceutical Machinery and Engineering (JSPME) are pleased to submit you our offers and comments concerning "Draft Guidance for Industry on Sterile Drug Products Produced by Aseptic Processing" (Docket No. 03D-0382, CDER 1997112). We hope that you will consider our comments, and this guidance will be a very fruitful guidance for PAT. This document prepared by using Microsoft® Word 2002 is also sent to [FDA\(coryj@cder.fda.gov\)](mailto:FDA(coryj@cder.fda.gov)) by e-mail today.

We would be much obliged if you give us FDA review of our comments by letter or by e-mail.

Contacts;

Katsuhide Terada, Ph. D.

Chairman of the Japan Society of Pharmaceutical Machinery and Engineering (JSPME)

Merino Bldg. 5<sup>th</sup> floor, 1-28 Kanda Suda-cho,

Chiyoda-ku, Tokyo 101-0041

Japan

Tel: +81-3-3252-3048

E-mail: [info@seikiken.or.jp](mailto:info@seikiken.or.jp)

2003D-0382

C20

For your references, we, Japan Society of Pharmaceutical Machinery and Engineering (JSPME) are nonprofit industry group which is operated mainly in Japan with approx. 810 members, and we were established Oct. 1990 in order to seek the ideal pharmaceutical production through the research, development and discussion based on both theoretical and practical concept in cooperating with industry, government and academia.

Sincerely,



Katsuhide Terada, Ph. D.

Chairman

Japan Society of Pharmaceutical Machinery and Engineering (JSPME)

Merino Bldg. 5<sup>th</sup> floor, 1-28 Kanda Suda-cho,

Chiyoda-ku, Tokyo 101-0041

Japan

Tel: +81-3-3252-3048

E-mail: [info@seikiken.or.jp](mailto:info@seikiken.or.jp)

## Comments

Japan Society of Pharmaceutical Machinery and Engineering

### [I] Outline

1. FDA's view of the harmonization with the related guidance in EU or Japan should be addressed in this guidance.
2. The modification from the concept paper released on 27 September, 2002 should be described in this guidance.
3. It will be useful for us to know about FDA's prospect for this guidance.

### [II] Comments for each sections

1. More and concrete description about H<sub>2</sub>O<sub>2</sub> should be added into "APPENDIX 1: ASEPTIC PROCESSING ISOLATORS".
2. Criteria for assessing state by Mediafill test described in Line 932 -944 are too strict so that less strict criteria are requested.